At WIN's inaugural event, attendees were asked to respond to questions about gender biases. Getty Images

Last week, female engineers and entrepreneurs from across the state gathered for the inaugural Society for Petroleum Engineers Gulf Coast Section' Women-in-Energy Congress.

Attendees were able to hear from speakers, like Susan Dio, chairman and president of BP America, who delivered the keynote address, as well as opt into breakout sessions and discussions, like "The New Age of Startups."

Throughout the day, the attendees were asked to respond to questions regarding their experience as women in a male-dominated field. The results show that mentorship and communication are both keys to ending gender biases in the workplace, while things like politics and lack of female mentors hold back results.

When asked about how men could be allies in the workplace to women, over 48 percent of respondents said male coworkers could do a better job of checking their unconscious bias in themselves and in others.

More than 47 percent responded that the biggest positive impact for their careers has been a boss, mentor, or sponsor, and almost 70 percent of those polls said that direct managers or people in the C-suite had the greatest impact of eliminating gender biases in the workplace.

For women seeking support in their careers, it was clear from the event that the solution is looking to other women who may have been in similar situations. Almost 100 percent of respondents said they have considered or pursued a career change in the past — half of those wanted a career change to expand their skill set and over a third felt like they have growth opportunities in their current role.

Texas ranks as the top state for female entrepreneurs, so there is potential for success within larger companies. According to the speakers and conversations at WIN's event, there's a lot both women and men can do to end gender biases for future business operations.

Courtesy of WIN

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”